SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mike mulhearn who started this subject7/19/2001 10:51:20 PM
From: Extra Pale  Read Replies (2) of 438
 
Some notes from today's gzmo 2nd quarter conference call. Be aware that lots of questions were asked and lots of science was discussed; and unfortunately I understand little of the science -- strongly urge interested parties to listen directly to replay of the call.

Cash:
Cash on hand plus papa genz line of credit sufficient to fund operations until 3rd qtr. 2002. Was suggested that potential partnerships this year could provide upfront cash.

Clinic: (lots of discussion)
1) Antigen specific melanoma trial results to be presented at ASH (12/01 assuming abstract is accepted)
2) Multi-valent peptide vaccine trials in melanoma to commence by year-end.
3) Melanoma, kidney, and breast cancer trials - enrollment underway.
4) Enrollment in trials using chemical and electro-fusion proccess to be operated in tandem (help, I don't completely follow the chemical fusion vs. electro fusion discussion)

ASCO:
1) Schering Plough discontinued p53 ovarian gene therapy trial due to interim review indicating that endpoints would not be met. This will delay receipt of potential milestones and royalty payments.
2) SAGE is great... (listen yourself!) Expect some royalty income in 3rd quarter from Invitrogen reagent sales. SAGE user conference 9/9
3) "alot of visability by major pharma and biotech and antibody companies" surrounding gzmo ability to discover antigens related to antibody and anti-angiogenesis. help! this is probably important ;-)

Collaborations:
Certain amount of arrogance here - on track for two collaborations by year-end:
1) Antigen discovery - unlike purdue pharm deal, will likely seek codevelopment rights
2) Antibody/anti-angiogenesis collaboration, will seek significant codevelopment and commercialization rights.

My Impressions:
Cash position concerns me tho Gail seem to suggest that cash will come from a new partner this year. Also sounded like they intend to finalize a major (lucrative) antibody partner before year-end. Vaccine trials on track, lots of discussion of patent estate. Good call, better deliver two new MAJOR partners this year....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News